Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
11,880
Total Claims
$1.4M
Drug Cost
519
Beneficiaries
$2,732
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+94%
Cost per patient vs peers
$2,732 vs $1,411 avg
+45%
Brand preference vs peers
15.4% vs 10.6% avg
Brand vs Generic
Brand: 1,826 claims · $1.2M
Generic: 9,999 claims · $232K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dapagliflozin Propanediol | 149 | $144K |
| Sitagliptin Phos/Metformin Hcl | 116 | $105K |
| Levothyroxine Sodium | 581 | $65K |
| Rivaroxaban | 56 | $62K |
| Apixaban | 36 | $52K |
| Insulin Glargine,hum.Rec.Anlog | 74 | $42K |
| Budesonide/Formoterol Fumarate | 77 | $34K |
| Ticagrelor | 31 | $33K |
| Empagliflozin | 22 | $32K |
| Insulin Lispro | 30 | $27K |
| Sitagliptin Phosphate | 17 | $26K |
| Empagliflozin/Metformin Hcl | 23 | $24K |
| Famotidine | 1,262 | $20K |
| Linaclotide | 24 | $19K |
| Linagliptin/Metformin Hcl | 11 | $17K |
Prescribing Profile
Patient Profile
71
Avg Age
72%
Female
1.64
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data